Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, London, United Kingdom.
Hôpital Paul Brousse, Villejuif, France; Unité INSERM U785, Paris, France.
J Hepatol. 2014 Nov;61(5):1038-47. doi: 10.1016/j.jhep.2014.06.012. Epub 2014 Jun 17.
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a frequent syndrome (30% prevalence), characterized by acute decompensation of cirrhosis, organ failure(s) and high short-term mortality. This study develops and validates a specific prognostic score for ACLF patients.
Data from 1349 patients included in the CANONIC study were used. First, a simplified organ function scoring system (CLIF Consortium Organ Failure score, CLIF-C OFs) was developed to diagnose ACLF using data from all patients. Subsequently, in 275 patients with ACLF, CLIF-C OFs and two other independent predictors of mortality (age and white blood cell count) were combined to develop a specific prognostic score for ACLF (CLIF Consortium ACLF score [CLIF-C ACLFs]). A concordance index (C-index) was used to compare the discrimination abilities of CLIF-C ACLF, MELD, MELD-sodium (MELD-Na), and Child-Pugh (CPs) scores. The CLIF-C ACLFs was validated in an external cohort and assessed for sequential use.
The CLIF-C ACLFs showed a significantly higher predictive accuracy than MELDs, MELD-Nas, and CPs, reducing (19-28%) the corresponding prediction error rates at all main time points after ACLF diagnosis (28, 90, 180, and 365 days) in both the CANONIC and the external validation cohort. CLIF-C ACLFs computed at 48 h, 3-7 days, and 8-15 days after ACLF diagnosis predicted the 28-day mortality significantly better than at diagnosis.
The CLIF-C ACLFs at ACLF diagnosis is superior to the MELDs and MELD-Nas in predicting mortality. The CLIF-C ACLFs is a clinically relevant, validated scoring system that can be used sequentially to stratify the risk of mortality in ACLF patients.
慢加急性肝衰竭(ACLF)是一种常见的综合征(患病率为 30%),其特征为肝硬化急性失代偿、器官功能衰竭和高短期死亡率。本研究开发并验证了一种用于 ACLF 患者的特定预后评分系统。
使用来自 CANONIC 研究的 1349 例患者的数据。首先,使用来自所有患者的数据开发了一种简化的器官功能评分系统(CLIF 联盟器官衰竭评分,CLIF-C OFs),以诊断 ACLF。随后,在 275 例 ACLF 患者中,将 CLIF-C OFs 与另外两个死亡率的独立预测因素(年龄和白细胞计数)相结合,开发了一种特定的 ACLF 预后评分(CLIF 联盟 ACLF 评分[CLIF-C ACLFs])。使用一致性指数(C 指数)比较 CLIF-C ACLF、MELD、MELD-钠(MELD-Na)和 Child-Pugh(CPs)评分的区分能力。在外部队列中验证了 CLIF-C ACLFs,并评估了其连续使用情况。
CLIF-C ACLFs 显示出显著更高的预测准确性,优于 MELDs、MELD-Nas 和 CPs,在 CANONIC 和外部验证队列中,在 ACLF 诊断后所有主要时间点(28、90、180 和 365 天)都降低了(19-28%)相应的预测误差率。在 ACLF 诊断后 48 小时、3-7 天和 8-15 天计算的 CLIF-C ACLFs 显著更好地预测了 28 天死亡率。
CLIF-C ACLFs 在预测死亡率方面优于 MELDs 和 MELD-Nas。CLIF-C ACLFs 是一种临床相关的验证评分系统,可用于连续分层 ACLF 患者的死亡率风险。